Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This study found that combined hormonal contraceptives containing ethenyl estradiol and cyproterone acetate improved acne, hirsutism, menstrual irregularity, and dysmenorrhea in patients with polycystic ovarian syndrome, with most participants showing significant symptom improvement after 6 to 12 months.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

In this case report, four sessions of the Broad Ligament Maneuver were associated with improvements in ovarian function and regression of PCOS symptoms, including normalizing menstrual flow and decreasing hirsutism.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

This study reported that the pseudoceramide bis-oleamido isopropyl alcohol (BOI) promotes hair growth in ex vivo cultured human hair follicles, likely by enhancing sphingolipid synthesis in dermal papilla cells.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This article notes that low-dose systemic minoxidil combined with antiandrogen therapy is effective for treating female pattern hair loss, though hypertrichosis can occur in a significant percentage of patients.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.

This meta-analysis reported that dienogest and combined oral contraceptives had comparable efficacy and tolerability for endometriosis treatment, with therapeutic choice suggested to be based on patient preference and clinical history.